Michael Gubanski

Summary

Affiliation: Karolinska University Hospital
Country: Sweden

Publications

  1. ncbi Capecitabine as third line therapy in patients with advanced colorectal cancer
    Michael Gubanski
    Department of Oncology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Acta Oncol 44:236-9. 2005
  2. doi Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Michael Gubanski
    Department of Oncology, Karolinska University Hospital at Södersjukhus, Sjukhusbacken 10, SE 118 83, Stockholm, Sweden
    Gastric Cancer 13:155-61. 2010
  3. ncbi Advances in the treatment of patients with gastric adenocarcinoma
    Theodoros Foukakis
    Department of Oncology, Karolinska University Hospital Södersjukhuset, Stockholm, Sweden
    Acta Oncol 46:277-85. 2007

Detail Information

Publications3

  1. ncbi Capecitabine as third line therapy in patients with advanced colorectal cancer
    Michael Gubanski
    Department of Oncology, Karolinska University Hospital Huddinge, Stockholm, Sweden
    Acta Oncol 44:236-9. 2005
    ..in patients with irinotecan- and oxaliplatin-combination resistant advanced colorectal cancer...
  2. doi Randomized phase II study of sequential docetaxel and irinotecan with 5-fluorouracil/folinic acid (leucovorin) in patients with advanced gastric cancer: the GATAC trial
    Michael Gubanski
    Department of Oncology, Karolinska University Hospital at Södersjukhus, Sjukhusbacken 10, SE 118 83, Stockholm, Sweden
    Gastric Cancer 13:155-61. 2010
    ..We compared sequential administration of docetaxel and irinotecan, both in combination with infused 5-fluorouracil/leucovorin (5-Fu/Lv), and randomly assigned patients to start with either of the two...
  3. ncbi Advances in the treatment of patients with gastric adenocarcinoma
    Theodoros Foukakis
    Department of Oncology, Karolinska University Hospital Södersjukhuset, Stockholm, Sweden
    Acta Oncol 46:277-85. 2007
    ..However, the response rates have generally been moderate and there is no consensus on the optimal combination of cytotoxic agents and the potential role of more recently developed "targeted therapies"...